<DOC>
	<DOCNO>NCT00228540</DOCNO>
	<brief_summary>An 8-week , Open-Label Study Characterize Response Modafinil ( 85mg Film-Coated Tablet ) Treatment Dosages 425mg/Day Children Adolescents Attention-Deficit/Hyperactivity Disorder ( ADHD ) ( With Open-Ended Extension Period )</brief_summary>
	<brief_title>Study Assess Satisfaction With Modafinil Treatment Children Adolescents With ADHD</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<criteria>Patients include study follow criterion meet : Written inform consent/assent obtain . The patient boy girl 6 17 year age ( inclusive ) screen visit , patient parent/legal guardian Englishspeaking . The patient previous diagnosis ADHD currently receive medication treatment ADHD . The patient , patient 's parent/legal guardian , dissatified ( VAS score &lt; 50 ) current ADHD medication ( medication reason dissatisfaction document ) . The patient good health determine medical psychiatric history , screen physical examination , clinical laboratory evaluation . Girls postmenarche sexually active , must negative urine pregnancy test prior baseline visit , must use medically acceptable method birth control , must agree continue use method duration study ( 30 day participation study ) . Acceptable method birth control include follow : barrier method spermicide ; steroidal contraceptive ( eg , oral , transdermal , implant , inject ) conjunction barrier method ; intrauterine device ( IUD ) ; abstinence . The patient 's parent/legal guardian must willing able comply study procedure restriction . Patients exclude participate study 1 follow criterion meet : The patient current psychiatric comorbidity , include limited depression mood disorder , pervasive mental disorder , require pharmacotherapy . The patient satisfy current ADHD medication side effect . The patient use prescription medication ADHD psychoactive property ( eg , amphetamine , dextroamphetamine , methylphenidate , pemoline , atomoxetine ) baseline visit . The patient use monoamine oxidase ( MAO ) inhibitor within 1 week baseline visit . The patient use investigational drug within 1 month screen visit . The patient know clinically significant drug sensitivity modafinil inactive ingredient . The patient pregnant lactating . ( Any patient become pregnant study withdrawn study ) .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>